•  
  •  
 

Abstract

Background: Basal cell carcinoma (BCC) is one of the most common skin cancers that may result in local invasion and poor cosmetic appearance if left untreated or inadequately excised with tumor remaining in the surgical margin. BCC incidence rates are increasing but the number of studies from Thailand is limited.

Objective: To study the clinical and histopathological features of BCC in Thailand and classify lesions as Low- or high-risk and determine factors associated with infiltrated surgical margins.

Materials and Methods: This is a retrospective descriptive study that was conducted at Thammasat University Hospital, Thailand between January 2017 to September 2023.

Results: A total of 75 excisional specimens were obtained from 71 patients of mean age 69 years and a male to female ratio of 0.64:1. Mixed and pure histological subtypes numbered 49 (65.3%) and 26 (34.7%), respectively, and nodular types predominated in both subtypes: 28/49 (57.1%) and 11/26 (42.3%). Four factors were associated with infiltrated surgical margins (p < 0.05): tumor size > 1.2 cm, tumor depth > 4.4 mm, tumor location in high-risk areas, and tumor invasion into subcutis or deeper levels. The latter was associated with high-risk subtypes (p < 0.001) whilst pigmentation was associated with low-risk subtypes (p < 0.05).

Conclusion: Our data is broadly consistent with other case series. Preoperative evaluation to determine BCC subtype (low-/ high-risk), tumor depth, location, and level of invasion from punch or incisional biopsies should be performed to ensure adequate surgical excision and tumor free margins.

References

"1. Rojanamartin J, Ukranum W, Supaattagorn P, et al. editors. Cancer in Thailand vol X, 2016- 2018. Bangkok: n.p. 2021. 2. Imsamran W, Pattatang A, Supaattagorn P, et al. editors. Cancer in Thailand Vol.IX, 2013- 2015. Bangkok: New Thammada Press; 2018. 3. WHO Classification of Tumours Editorial Board. Skin tumours [Internet; beta version ahead of print]. Lyon (France): International Agency for Research on Cancer; 2023 [cited 2023 March 8th]. (WHO classification of tumours series, 5th ed.; vol. 12). Available from: https://tumourclassification.iarc.who.int/chapters/64 4. Zbar RI, Cottle WI, Skin tumors I: nonmelanoma skin tumors, Selected Readings in Plastic Surgery. 2000;9 (article 5). 5. Bittner GC, Cerci FB, Kubo EM, Tolkachjov SN. Mohs micrographic surgery: a review of indications, technique,outcomes, and considerations. An Bras Dermatol. 2021;96:263-77. 6. Shanoff LB, Spira M, Hardy SB. Basal cell carcinoma: a statistical approach to rational management. Plast Reconstr Surg. 1967;39(6):619-24. 7. Abbas OL, Borman H. Basal cell carcinoma: a single-center experience. ISRN Dermatol. 2012;2012:246542. 8. Christenson LJ, Borrowman TA, Vachon CM, et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA. 2005;294(6):681-90. 9. Szewczyk M, Pazdrowski J, Golusiński P, et al. Basal cell carcinoma in farmers: an occupation group at high risk. Int Arch Occup Environ Health. 2016;89(3):497-501. 10. Bourlidou E, Vahtsevanos K, Kyrgidis A, et al. Risk factors for local recurrence of basal cell carcinoma and cutaneous squamous cell carcinoma of the middle third of the face: a 15-year retrospective analysis based on a single centre. Eur J Dermatol. 2019;29(5):490-9. 11. Chlebicka I, Stefaniak A, Matusiak Ł, Szepietowski JC. Basal cell carcinoma: what new can be learned about the most common human cancer? A cross-sectional prospective study of 180 cases in a single centre. Postepy Dermatol Alergol. 2021;38(6):1086-91. 12. Goldberg DP. Assessment and surgical treatment of basal cell skin cancer. Clin Plast Surg. 1997;24(4):673-86. 13. Randle HW. Basal cell carcinoma. Identification and treatment of the high-risk patient. Dermatol Surg. 1996;22(3):255-61. 14. Bartoš V, Pokorný D, Zacharová O, et al. Recurrent basal cell carcinoma: a clinicopathological study and evaluation of histomorphological findings in primary and recurrent lesions. Acta Dermatovenerol Alp Pannonica Adriat. 2011;20(2):67-75. 15. Aai SZ, Hong AM. Treatment of basal cell carcinomas at high risk for recurrence [Internet]. UpToDate; [cited 2025 Mar 25]. Available from: https://www.uptodate.com/contents/treatment-of-basal-cell-carcinomas-at-high-risk-for-recurrence?topicRef=5335&source=see_link 16. Enache AO, Stepan AE, Mărgăritescu C, et al. Immunoexpression of p53 and COX-2 in basal cell carcinoma. Rom J Morphol Embryol. 2018;59(4):1115-20. 17. Girardi FM, Wagner VP, Martins MD, Abentroth AL, Hauth LA. Factors associated with incomplete surgical margins in basal cell carcinoma of the head and neck. Braz J Otorhinolaryngol. 2021;87(6):695-701. 18. Ansarin H, Daliri M, Soltani-Arabshahi R. Expression of p53 in aggressive and non-aggressive histologic variants of basal cell carcinoma. Eur J Dermatol. 2006;16(5):543-7. 19. Cho M, Lee J, James CL, Marshman G, Huilgol SC. Scalp Basal Cell Carcinoma: Review of 2,202 Cases. Dermatol Surg. 2016;42(7):834-41. 20. Karampinis E, Lallas A, Lazaridou E, Errichetti E, Apalla Z. Race-specific and skin of color dermatoscopic characteristics of skin cancer: a literature review. Dermatol Pract Concept. 2023;13(4 S1):e2023311S. "

Download

Share

COinS